Patrick G Enright

Patrick G Enright has an estimated net worth of $3.3 Billion. This is based on reported shares across multiple companies, which include VALENTIS INC, Inozyme Pharma, Inc., Lexeo Therapeutics, Inc., Axonics Modulation Technologies, Inc., Vera Therapeutics, Inc., RAPID MICRO BIOSYSTEMS, INC., CORCEPT THERAPEUTICS INC, COLLEGIUM PHARMACEUTICAL, INC, Jazz Pharmaceuticals plc, Esperion Therapeutics, Inc., Tricida, Inc., Talaris Therapeutics, Inc., Sierra Oncology, Inc., Vaxcyte, Inc., 89bio, Inc., Eargo, Inc., Kala Pharmaceuticals, Inc., Venus Concept Inc., Molecular Templates, Inc., Aptinyx Inc., Aimmune Therapeutics, Inc., SEQUENOM INC, Zenas BioPharma, Inc., BioAge Labs, Inc., and Veradermics, Inc.

2020 was Patrick G Enright's most active year for acquiring shares with 29 total transactions. Patrick G Enright's most active month to acquire stocks was the month of April. 2015 was Patrick G Enright's most active year for disposing of shares, totalling 130 transactions. Patrick G Enright's most active month to dispose stocks was the month of January. 2026 saw Patrick G Enright paying a total of $18,306,451.60 for 5,328,036 shares, this is the most they've acquired in one year. In 2014 Patrick G Enright cashed out on 2,800,925 shares for a total of $111,949,611.98, their largest year based on trade value.